SCHEMBL2664657

SCHEMBL2664657

Cc1nnc(NC(=O)c2cc(OCc3ccccc3Cl)cc(OCc3ccccc3Cl)c2)s1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.54
TP53 P04637 2/20 0.54
NPC1 O15118 3/20 0.54
RAB9A P51151 3/20 0.54
HPGD P15428 1/20 0.51
KDM4E B2RXH2 2/20 0.50
GCK P35557 1/20 0.48
LMNA P02545 1/20 0.48
ALDH1A1 P00352 2/20 0.48
RXFP1 Q9HBX9 1/20 0.48
MEN1 O00255 1/20 0.48
GAA P10253 1/20 0.48
ALOX15 P16050 1/20 0.48
TSHR P16473 1/20 0.48
KMT2A Q03164 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
NR4A2 P43354 1/20 0.47
CSNK2A2 P19784 1/20 0.47
CSNK2A1 P68400 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2664665 0.88 GCK (0.49) NPC1RAB9AKDM4EGCKLMNA
SCHEMBL2664649 0.88 POLQ (0.51) SMN1; SMN2TP53NPC1RAB9AKDM4E
SCHEMBL2664683 0.87 GCK (0.58) SMN1; SMN2TP53NPC1RAB9AHPGD
SCHEMBL2664655 0.86 GCK (0.52) NPC1RAB9AGCKLMNAALDH1A1
SCHEMBL2664658 0.86 HTT (0.45) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL2664648 0.85 SMN1; SMN2 (0.60) SMN1; SMN2TP53NPC1RAB9AHPGD
SCHEMBL2664586 0.85 GCK (0.46) TP53NPC1RAB9AGCKLMNA
SCHEMBL2664659 0.82 KDM4E (0.60) SMN1; SMN2TP53NPC1RAB9AHPGD
SCHEMBL2664647 0.82 GCK (0.49) SMN1; SMN2NPC1RAB9AHPGDKDM4E
SCHEMBL2664682 0.81 GCK (0.64) SMN1; SMN2TP53NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-7951830-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2011-05-31 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE ASTRAZENECA AB (SE) 2009-09-10 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-7524957-B2 Compounds effecting glucokinase ASTRAZENECA AB (SE) 2009-04-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-20080207636-A1 Compounds Effecting Glucokinase ASTRAZENECA AB (SE) 2008-08-28 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed
US-7390908-B2 Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes ASTRAZENECA AB (SE) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207636-A1 Compounds Effecting Glucokinase GCKR, GCK, SLC5A2 SMN1; SMN2 1886/4885TP53 4054/4885NPC1 1139/4885
US-20090227592-A1 COMPOUNDS EFFECTING GLUCOKINASE GCKR, GCK, SLC5A2 SMN1; SMN2 1886/4885TP53 4054/4885NPC1 1139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.